CTMX 10-Q: SEC filing
CytomX Therapeutics
Filed with the SEC on · accession 0001193125-26-449739
CTMX filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -8.9% by the first close after the filing.
Summary of the filing
CytomX Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results and ongoing collaboration agreements with partners including Regeneron, Amgen, Moderna, Astellas, and Bristol Myers Squibb.
Key details
How CTMX stock reacted
Close before
$2.35
Nov 4, 2026
First close after
-8.94%
$2.14
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for CTMX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CTMX?
Click hereFrequently asked questions
What did CTMX file with the SEC on Nov 5, 2026?
CTMX filed a 10-Q (SEC filing). CytomX Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results and ongoing collaboration agreements with partners including Regeneron, Amgen, Moderna, Astellas, and Bristol Myers Squibb.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did CTMX stock react to this filing?
CTMX closed at $2.35 before the filing and $2.14 on Nov 5, 2026 (-8.94%).
Other CTMX SEC filings
Get alerts when CTMX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days